- Home
- EYPT vs TNGX Comparison
EYPT vs TNGX Comparison
Compare EYPT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- TNGX
- Stock Information
- Founded
- EYPT 1987
- TNGX 2014
- Country
- EYPT United States
- TNGX United States
- Employees
- EYPT N/A
- TNGX N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- TNGX Health Care
- Exchange
- EYPT Nasdaq
- TNGX Nasdaq
- Market Cap
- EYPT 390.0M
- TNGX 317.4M
- IPO Year
- EYPT 2005
- TNGX N/A
- Fundamental
- Price
- EYPT $5.36
- TNGX $1.36
- Analyst Decision
- EYPT Strong Buy
- TNGX Strong Buy
- Analyst Count
- EYPT 7
- TNGX 7
- Target Price
- EYPT $24.00
- TNGX $12.33
- AVG Volume (30 Days)
- EYPT 610.5K
- TNGX 579.6K
- Earning Date
- EYPT 05-07-2025
- TNGX 05-12-2025
- Dividend Yield
- EYPT N/A
- TNGX N/A
- EPS Growth
- EYPT N/A
- TNGX N/A
- EPS
- EYPT N/A
- TNGX N/A
- Revenue
- EYPT $56,042,000.00
- TNGX $40,990,000.00
- Revenue This Year
- EYPT N/A
- TNGX N/A
- Revenue Next Year
- EYPT N/A
- TNGX N/A
- P/E Ratio
- EYPT N/A
- TNGX N/A
- Revenue Growth
- EYPT 12.04
- TNGX 10.09
- 52 Week Low
- EYPT $3.91
- TNGX $1.11
- 52 Week High
- EYPT $21.26
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EYPT 43.45
- TNGX 44.43
- Support Level
- EYPT $5.75
- TNGX $1.07
- Resistance Level
- EYPT $6.29
- TNGX $1.45
- Average True Range (ATR)
- EYPT 0.47
- TNGX 0.16
- MACD
- EYPT -0.11
- TNGX 0.01
- Stochastic Oscillator
- EYPT 0.00
- TNGX 44.34
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.